Key Highlights

  • Cash, cash equivalents and short-term investments totaled USD 254.7 million at September 30, 2026, made up of USD 10.8 million in cash and USD 243.9 million in Money Market and U.S. Treasury holdings.
  • Because market Capitalization fell for a sustained period and LDD sales volumes declined, the company ran a recoverability test on its long-lived assets, which passed with no Impairment recorded.
  • A securities class action filed July 22, 2025 cleared a motion to dismiss on May 21, 2026, and discovery is now underway.
  • A hypothetical 1.00% shift in interest rates would not materially change the Fair Value of the marketable securities or interest income.

Falling Share Value and LDD Volumes Prompt the Review

On November 3, 2026, RxSight (NASDAQ:RXST) submitted its 10-Q covering the quarter that closed September 30, 2026. During the quarter it flagged possible impairment of long-lived assets, citing a sustained drop in market capitalization and weaker sales of its LDD product line, an abbreviation the filing uses without expanding. Treating its Assets as one group, it compared estimated undiscounted future cash flows with their carrying amount. Those cash flows were larger than the carrying value, so no impairment loss was booked.

Why the Impairment Judgment Carries Weight

An impairment test asks whether the future operating cash flows of an asset group will cover its book value. When they fall short, the asset is marked down to fair value, typically derived from discounted cash flows. The filing warns that such estimates rest on assumptions about growth, margins, discount rates and regulation, and that long-lived assets could be impaired later if those expectations fail. Any write-down would be non-cash but would still shrink reported Earnings and assets. Liquidity appears comfortable, with USD 254.7 million of cash and short-term investments largely in money market funds and Treasury securities that mature within twelve months, held for liquidity and capital preservation. Foreign currency exposure is described as de minimis. Revenue and earnings figures were not included in the extract used here.

Securities Suit, Supplier Concentration and Next Milestones

The legal section carries more weight. A proposed class action lodged July 22, 2025 in the Central District of California federal court contends that the company and some executives made misleading remarks about Demand and forecasts. Related cases were consolidated October 6, 2025, a motion to dismiss was filed February 13, 2026 and denied May 21, 2026, and the company filed its answer June 9, 2026. Plaintiffs seek unspecified damages, and a Shareholder derivative suit was filed August 18, 2025 against certain officers and directors. The company also relies on single and sole source suppliers without long-term deals, buys under purchase orders covering 18 to 24 months, and points to tariffs and Inflation as uncertainties. Allegations are not findings, and the outcome is uncertain. Next checkpoints include further LDD sales commentary and litigation rulings.

Where Things Stand

RxSight (NASDAQ:RXST) ran the test because accounting standards call for one when a sustained drop in Market Value and weakening product volumes appear, not because it had already booked a loss. It passed, and management said disclosure controls were effective. The overall read is cautious: USD 254.7 million of liquidity is a real strength, but falling LDD volumes, the active class action and supplier concentration are substantive risks. The extract does not show quarterly revenue or profit, so the size of the slowdown is unclear. The next earnings report, litigation developments and any change in the impairment assessment are what to watch.